Nicole Germino
Stock Analyst
(n/a)
# 4,429
Out of 4,648 analysts
18
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Buy | $100 → $105 | $68.09 | +54.21% | 7 | Nov 1, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $12.19 | +72.27% | 1 | Sep 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $21 | $14.87 | +41.22% | 1 | Jun 28, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Hold | n/a | $1.74 | - | 4 | Nov 7, 2023 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $16.98 | +41.34% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $4.37 | - | 2 | Sep 3, 2021 |
Insmed
Nov 1, 2024
Reiterates: Buy
Price Target: $100 → $105
Current: $68.09
Upside: +54.21%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $12.19
Upside: +72.27%
Y-mAbs Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $21
Current: $14.87
Upside: +41.22%
Sangamo Therapeutics
Nov 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.74
Upside: -
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $16.98
Upside: +41.34%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $4.37
Upside: -